Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2–Q3, PTSD Plan for 2027

Key Points

• DT120 readouts are expected across late Q2–Q3 — MDD (EMERGE) in late Q2, GAD (VOYAGE) in early Q3 and GAD (PANORAMA) in late Q3 — and Definium plans a phase III PTSD study in 2027.
• A blinded sample-size re-estimation cut PANORAMA’s target to 200 patients with ~99% power after lower-than-expected variability and a ~6% not-evaluable rate, while VOYAGE enrollment is complete and PANORAMA screening has closed.
• Commercial planning targets patients who failed ≥2 therapies (an initial market ~4 million), with payers likely to benchmark pricing to esketamine (roughly $28,000–$70,000 annually) and Definium holding IP protection into the early–mid 2040s plus regulatory exclusivity.

Definium Therapeutics NASDAQ: DFTX used a company event to outline its late-stage development plans for DT120, an oral disintegrating tablet (ODT) formulation of LSD being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with an additional phase III study in post-traumatic stress disorder (PTSD) planned for 2027. Management also discussed trial execution updates, the rationale for its study designs, and early commercial planning ahead of multiple anticipated top-line readouts this year.

Leadership highlights and development timeline

CEO and board director Rob Barrow framed the company’s focus around unmet need in anxiety and depression and the limitations of current treatment pathways, which he described as cycles of trial-and-error with chronic medications and burdensome side effects. Barrow emphasized the potential of a single-dose intervention administered in a monitored clinical setting, saying the company’s goal is to provide “the best support, the best care” for patients if DT120 is approved.

Barrow said Definium expects three pivotal readouts across late Q2 through Q3. He stated that the company is “on track” for a late Q2 top-line readout in MDD (EMERGE), followed by an early Q3 readout for its first GAD phase III study (VOYAGE), and a late Q3 readout for the second GAD phase III study (PANORAMA).

Phase III execution updates and sample size adjustment

Barrow provided updates from a blinded sample size re-estimation (SRE) conducted in Definium’s two phase III GAD trials, which evaluated assumptions such as standard deviation and not-evaluable rates. He said the company observed lower-than-planned variability and not-evaluable rates, including a “6% not evaluable rate” in PANORAMA, which he characterized as supporting high data quality and patient retention.

Based on the SRE, Definium reduced the PANORAMA target enrollment to 200 patients. Barrow said the trial has “99% power,” and management indicated the design is structured so that “less than a 2.5 point delta” could be sufficient for statistical success under the revised assumptions. Barrow also said enrollment is complete in VOYAGE and that screening has closed in PANORAMA after exceeding the updated target, with already-screening patients allowed to continue for practical and ethical reasons.

Clinical rationale: overlap across GAD, MDD, and PTSD

Chief Medical Officer Dan Karlin discussed how Definium views GAD and MDD as overlapping symptom clusters rather than strictly separated categories, noting that anxiety and depression frequently coexist. Karlin described anxiety as often a “background state” that can persist over time, with major depressive episodes increasing the likelihood of subsequent episodes and potentially worsening baseline anxiety. He argued that diagnostic criteria and rating scales show “tremendous overlap,” and said correlations between symptoms on the HAM-A (anxiety) and MADRS (depression) support confidence in DT120’s potential across these conditions.

Karlin said Definium plans to enter PTSD with a phase III study starting in 2027, calling PTSD a “third leg of the stool of neurotic illness.” He stated that PTSD shares many symptoms with GAD and MDD but has an attributable cause, and that overlap across definitions supports Definium’s confidence in pursuing a PTSD label claim if DT120 is approved.

Study design choices: measuring drug effect and session logistics

Karlin emphasized that Definium’s trials are designed to assess drug effect “in the absence of any sort of dyadic psychotherapeutic intervention,” including no preparatory therapy, no in-room therapy during dosing, and no psychotherapy afterward. He said the company made those choices early and believes subsequent industry discussion has moved toward similar approaches.

He also detailed Definium’s eligibility process, which includes site assessments and two sets of blinded remote central raters: one for diagnostic confirmation (the MGH SAFER program) and one for severity and outcomes. Karlin said internal staff also review eligibility materials to ensure participants fit study criteria.

On dosing logistics, Karlin said the ODT formulation is intended to make the dosing day more efficient, with onset in “15–30 minutes” compared with about an hour for a standard tablet. He described peak and plateau effects around hours two to four, followed by waning effects and a “smooth” off-ramp. While phase III dosing sessions are eight hours, Karlin said Definium begins assessing readiness to leave at hour five using an “end of session checklist” developed with FDA input. He said the company aims to support potential labeling and REMS discussions around a “five to eight hour session length,” down from a fixed 12-hour minimum used in phase II.

Barrow later added that the company intends to present session-duration readiness data with top-line results and argued that requiring hours of monitoring after acute effects resolve would be an unnecessary burden if evidence supports earlier discharge for many patients.

Commercial planning, payer dynamics, and IP strategy

Chief Commercial Officer Matt Wiley said Definium is building a launch infrastructure “built for purpose” and argued there is no direct playbook for this kind of intervention, though esketamine (Spravato) provides an operational and reimbursement precedent. Wiley described “four converging forces” for launch readiness: provider readiness, reimbursement precedent, patient demand, and Definium’s timing.

Wiley distinguished prevalence estimates from the near-term launch opportunity, stating that while “50 million-plus” people may have GAD or MDD, Definium is focused on an initial population of patients failed by “two or more therapies,” which he said represents “over 4 million patients.” He also cited market research indicating growing clinician awareness of DT120 (formerly MM120), rising from 27% in a 2024 survey wave to 64% more recently, and said 58% of surveyed healthcare providers had positive views of DT120.

On reimbursement, Wiley said payers tend to anchor expectations to esketamine and anticipate DT120 annual pricing in line with Spravato, which he described as roughly “$28,000 a year” at the low end and “about $70,000 a year” at the high end based on dose and frequency. He added that payers expect coverage of FDA-approved treatments, typically with prior authorization and step edits, and pointed to reported esketamine approval rates “better than 85%” across commercial, Medicaid, and Medicare plans as a reference point for potential access over time.

Chief Financial Officer Brandi Roberts highlighted a “layered IP strategy,” stating that as a new chemical entity DT120 would be eligible for five years of exclusivity, potentially extended by 30 months in certain generic-challenge scenarios. She also said Definium has issued patents covering composition, formulation, and methods of use extending into the “early to mid-2040s,” with efforts underway to expand the portfolio and potentially extend protection further into the 2040s.

During Q&A, management reiterated expectations for the timing of readouts and said the primary endpoint timing differs by indication, with Karlin noting MDD’s primary outcome is MADRS at week six, while GAD’s primary outcome is HAM-A at week 12. Barrow said Definium plans to move quickly toward an NDA following the phase III program, emphasizing the pace of development since the IND opened in early 2022.

About Definium Therapeutics NASDAQ: DFTX

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.